These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30825466)

  • 1. Fevipiprant, a selective prostaglandin D
    Hardman C; Chen W; Luo J; Batty P; Chen YL; Nahler J; Wu Y; Pavord ID; Erpenbeck VJ; Sandham DA; Xue L; Ogg G
    J Allergy Clin Immunol; 2019 Jun; 143(6):2329-2333. PubMed ID: 30825466
    [No Abstract]   [Full Text] [Related]  

  • 2. Fevipiprant, a DP
    Shamri R; Dubois G; Erpenbeck VJ; Mankuta D; Sandham DA; Levi-Schaffer F
    Clin Exp Allergy; 2019 Feb; 49(2):255-257. PubMed ID: 30379368
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostaglandin D
    Carstensen S; Gress C; Erpenbeck VJ; Kazani SD; Hohlfeld JM; Sandham DA; Müller M
    Respir Res; 2021 Oct; 22(1):262. PubMed ID: 34620168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes.
    Poller B; Woessner R; Barve A; Tillmann HC; Vemula J; Nica A; Elbast W; Schiller H; End P; Camenisch G; Weiss M
    Pulm Pharmacol Ther; 2019 Aug; 57():101809. PubMed ID: 31195091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma.
    Issahaku AR; Agoni C; Soremekun OS; Kubi PA; Kumi RO; Olotu FA; Soliman MES
    Comb Chem High Throughput Screen; 2019; 22(8):521-533. PubMed ID: 31538888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.
    Sykes DA; Bradley ME; Riddy DM; Willard E; Reilly J; Miah A; Bauer C; Watson SJ; Sandham DA; Dubois G; Charlton SJ
    Mol Pharmacol; 2016 May; 89(5):593-605. PubMed ID: 26916831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D
    Chen W; Luo J; Ye Y; Hoyle R; Liu W; Borst R; Kazani S; Shikatani EA; Erpenbeck VJ; Pavord ID; Klenerman P; Sandham DA; Xue L
    J Immunol; 2021 Jun; 206(11):2714-2724. PubMed ID: 34011519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
    Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
    Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin D2 receptor 2 downstream signaling and modulation of type 2 innate lymphoid cells from patients with asthma.
    Gress C; Fuchs M; Carstensen-Aurèche S; Müller M; Hohlfeld JM
    PLoS One; 2024; 19(7):e0307750. PubMed ID: 39052598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.
    Pearson D; Weiss HM; Jin Y; Jaap van Lier J; Erpenbeck VJ; Glaenzel U; End P; Woessner R; Eggimann F; Camenisch G
    Drug Metab Dispos; 2017 Jul; 45(7):817-825. PubMed ID: 28442499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacology of the prostaglandin D
    Brightling C; Kulkarni S; Lambrecht BN; Sandham D; Weiss M; Altman P
    Pulm Pharmacol Ther; 2021 Jun; 68():102030. PubMed ID: 33826946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of a high specific activity methyl sulfone tritium isotopologue of fevipiprant (NVP-QAW039).
    Luu VT; Goujon JY; Meisterhans C; Frommherz M; Bauer C
    J Labelled Comp Radiopharm; 2015 May; 58(5):188-95. PubMed ID: 25881897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of prostaglandin D2 receptor antagonist: discovery of highly potent antagonists.
    Torisu K; Kobayashi K; Iwahashi M; Nakai Y; Onoda T; Nagase T; Sugimoto I; Okada Y; Matsumoto R; Nanbu F; Ohuchida S; Nakai H; Masaaki Toda
    Bioorg Med Chem; 2004 Sep; 12(17):4685-700. PubMed ID: 15358295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DP
    Saunders R; Kaul H; Berair R; Gonem S; Singapuri A; Sutcliffe AJ; Chachi L; Biddle MS; Kaur D; Bourne M; Pavord ID; Wardlaw AJ; Siddiqui SH; Kay RA; Brook BS; Smallwood RH; Brightling CE
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a new class of potent, selective, and orally active prostaglandin D2 receptor antagonists.
    Torisu K; Kobayashi K; Iwahashi M; Nakai Y; Onoda T; Nagase T; Sugimoto I; Okada Y; Matsumoto R; Nanbu F; Ohuchida S; Nakai H; Toda M
    Bioorg Med Chem; 2004 Oct; 12(20):5361-78. PubMed ID: 15388164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2.
    Armer RE; Ashton MR; Boyd EA; Brennan CJ; Brookfield FA; Gazi L; Gyles SL; Hay PA; Hunter MG; Middlemiss D; Whittaker M; Xue L; Pettipher R
    J Med Chem; 2005 Oct; 48(20):6174-7. PubMed ID: 16190744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
    Erpenbeck VJ; Vets E; Gheyle L; Osuntokun W; Larbig M; Neelakantham S; Sandham D; Dubois G; Elbast W; Goldsmith P; Weiss M
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):306-13. PubMed ID: 27310331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.
    Luker T; Bonnert R; Brough S; Cook AR; Dickinson MR; Dougall I; Logan C; Mohammed RT; Paine S; Sanganee HJ; Sargent C; Schmidt JA; Teague S; Thom S
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6288-92. PubMed ID: 21944852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin D₂ receptor CRTH2 antagonists for the treatment of inflammatory diseases.
    Chen JJ; Budelsky AL
    Prog Med Chem; 2011; 50():49-107. PubMed ID: 21315928
    [No Abstract]   [Full Text] [Related]  

  • 20. Fevipiprant, an oral prostaglandin DP
    Bateman ED; Guerreros AG; Brockhaus F; Holzhauer B; Pethe A; Kay RA; Townley RG
    Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28838980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.